Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R G Finch

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Drugs|January 1, 1995
The role of new quinolones in the treatment of respiratory tract infectionsR G Finch
The Journal of Antimicrobial Chemotherapy|March 25, 1998
Design of clinical trials in sepsis: problems and pitfallsR G Finch
British Medical Journal (Clinical Research Ed.)|January 24, 1987
Time for action on hepatitis B immunisationR G Finch
The Journal of International Medical Research|November 25, 2000
Introduction: antibiotic short-course therapy---where are the limits?R G Finch
British Medical Journal (Clinical Research Ed.)|October 13, 1984
Uncommon Haemophilus infectionsR G Finch
Journal of Chemotherapy (Florence, Italy)|May 1, 1997
In-vitro antimicrobial susceptibility testing: does it really matter?R G Finch
Drug Safety|January 1, 1993
The withdrawal of temafloxacin. Are there implications for other quinolones?R G Finch
British Journal of Hospital Medicine|November 13, 1994
HCV infection in blood donorsR G Finch
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 1, 1990
The clinical evaluation of antibacterial drugs: guidelines of the British Society for Antimicrobial ChemotherapyR G Finch
Drugs|January 1, 1996
Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical useR G Finch
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Drugs|January 1, 1995
The role of new quinolones in the treatment of respiratory tract infectionsR G Finch
The Journal of Antimicrobial Chemotherapy|March 25, 1998
Design of clinical trials in sepsis: problems and pitfallsR G Finch
British Medical Journal (Clinical Research Ed.)|January 24, 1987
Time for action on hepatitis B immunisationR G Finch
The Journal of International Medical Research|November 25, 2000
Introduction: antibiotic short-course therapy---where are the limits?R G Finch
British Medical Journal (Clinical Research Ed.)|October 13, 1984
Uncommon Haemophilus infectionsR G Finch
Journal of Chemotherapy (Florence, Italy)|May 1, 1997
In-vitro antimicrobial susceptibility testing: does it really matter?R G Finch
Drug Safety|January 1, 1993
The withdrawal of temafloxacin. Are there implications for other quinolones?R G Finch
British Journal of Hospital Medicine|November 13, 1994
HCV infection in blood donorsR G Finch
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 1, 1990
The clinical evaluation of antibacterial drugs: guidelines of the British Society for Antimicrobial ChemotherapyR G Finch
Drugs|January 1, 1996
Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical useR G Finch
Pageof 12